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All amyloid comprises fibrillar polymers of tightly associated protein mono-
mers. Central to the fibril structure is a highly ordered β-pleated sheet domain 
although this interacting region may only be a relatively short stretch of each 
constituent polypeptide chain. Fibril formation begins as a nucleation event based 
either on the constituent monomer protein or its proteolytic fragment(s). The 
resulting fibrils are generally chemically inert and very stable.
Keywords: amyloid, fibril, β-sheet, polymer, nucleation
1. Introduction
The term “amyloid” is intrinsically a misnomer. It was derived in the nineteenth 
century to describe what was then thought to be amorphous material composed of 
carbohydrate (Gk “amyl,” starch) in both plants and pathologic specimens from 
humans and animals. In human pathology these deposits were identified in the 
kidney, liver, heart, brain, and elsewhere and were often associated with organ 
dysfunction. In 1942, Hass [1] showed that the material was largely protein, not 
carbohydrate. An important observation in 1959 [2] used electron microscopy to 
show that the material was not amorphous but, rather, consisted of long fibrils. 
Figure 1 shows an example of amyloid fibrils.
Subsequent studies have been directed to identifying the constituent proteins 
and clarifying the process(es) of fibril formation. Treatment for affected individu-
als depends upon addressing the underlying chemistry and biology. We will review 
these in turn.
Figure 1. 
Electron microscopic images of amyloid fibrils derived from synthetic sequences of Alzheimer β(1-42) 
polypeptides each containing different amino acid substitutions and yet forming characteristic fibrils, 
emphasizing the generalizability of amyloid fibril formation [3]. Copyright, 2005. National Academy of 
Sciences, used by permission.
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2. Protein constituent(s) of amyloid fibrils
Many types of disorders are associated with amyloid deposits. Different fibril 
proteins underlie different pathologic contexts. Table 1 presents examples of some 
types of amyloid diseases, the proteins from which their fibril proteins are derived, 
and their clinical associations. As will be noted below, it has become important to 
identify the precise molecular constituent(s) of the fibrils in order to establish the 
correct diagnosis and plan appropriate treatment.
In humans, the most frequently encountered pathologic amyloid fibrils are 
derived from fragments of immunoglobulin proteins. Some (but not all) immuno-
globulin light chains (both κ and λ) have stretches of amino acids that can form the 
basic unit of amyloid fibrils. These are usually found in association with clonal pro-
liferations of plasma cells which range from “monoclonal gammopathy of unknown 
significance” (i.e., “MGUS”) to disorders such as myeloma. The fibrils themselves 
can cause distortion of organ microanatomy leading to cell dysfunction, disrupted 
cell-cell communication and, ultimately, organ failure.
Another well-studied type of amyloid fibril is derived from fragments of a 
small (104 amino acid) serum protein called “serum amyloid A (SAA).” Deposits 
of this type of amyloid are characteristic of chronic inflammatory or infectious 
disorders. It is likely that many of the examples of “amyloid” disease described in 
the pre-antibiotic era were derived from SAA (examples include tuberculosis and 
osteomyelitis).
Many genetic variants of transthyretin (TTR), another small, 127 amino acid 
serum protein, are associated with familial forms of amyloid disease. Affected indi-
viduals show progressive neurologic and/or cardiac dysfunction with concomitant 
amyloid deposition [6]. In addition, some individuals develop TTR amyloid disease 
(particularly involving the heart) in the absence of an underlying mutation in the 
protein.
Amyloid fibrils and plaques are characteristic of the neurodegeneration of 
Alzheimer disease. In this case, the parent protein is a large membrane-spanning 
protein referred to as β-amyloid. Only a small fragment of the primary protein is 
found in amyloid fibrils [7]. Specific endoproteases release this fragment from the 
parent molecule. As Figure 1 shows, characteristic amyloid fibrils can be formed 
from Aβ(1-42) polypeptides with individual amino acid variation(s).
Parkinson disease is another disorder of the central nervous system associ-
ated with cellular depositions. In this case, α-synuclein accumulates in cells of the 
basal ganglia associated with loss of function. In neurons, relatively disorganized 
oligomers of α-synuclein appear first, and there is gradual compaction with β-sheet 
domains becoming prominent later [8, 9].
Considerable interest has arisen regarding prions. These are alternative 
conformations of proteins that can self-associate and self-propagate. First deter-
mined to be causative agents of “spongiform encephalopathy” in humans  
(e.g., Creutzfeldt-Jakob disease), prions also have become recognized as respon-
sible for transmissible neuropathies in animals (e.g., “mad cow” disease). Studies 
of Sup35 prions in yeast have been particularly informative, and multiple strains 
can be isolated [10].
Another interesting category of disorders associated with amyloid fibril forma-
tion includes polypeptide hormones. Many of these are originally stored in relatively 
concentrated form within membrane-enclosed secretory granules. Table 1 lists 
several associated types. In normal physiology dissociation of these organized 
structures must occur in order to release individual hormones [11]. In certain situa-
tions, however, these same hormones (or their precursors) can persist and become 
detected as fibrils.
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3. Fibril structure
All amyloid fibrils share a basic unit comprising a relatively short and (usu-
ally) contiguous stretch of amino acids whose three-dimensional contours can be 
accommodated in a β-pleated sheet conformation (both parallel and antiparallel 
assemblies are recognized in fibrils). Hydrogen bonds between the amide groups 
polarize each other. Van der Waals forces also develop between the β-sheets. Water 
molecules are displaced from between the faces of the sheets. These important 
features emphasize that protein precursors of amyloid fibrils are not in their native 
state—the constituent monomer is in an altered conformation, and this state may 
only be transient prior to nucleation. Thus, there is an array of polypeptide species 
that may underlie fibril formation; the most (transiently) stable and/or abundant 
species is most likely to be captured in a stable β-sheet.
As shown by Riek and Eisenberg [12], amyloids derived from different protein 
constituents may have very different β-sheet domains. In addition, these regions 
may be rather small in comparison with the length of the parent protein(s). This 
implies that only a fragment of the parent (i.e., longer) protein may be found in the 
ultimate amyloid fibril, and this, in turn, implies that cleavage of the parent protein 
is often part of the process of fibril formation. Figure 2 presents example details of 
the particularly well-studied Alzheimer Aβ(1-42) fibril.
The β-pleated sheet topology of the basic interacting region permits individual 
regions to stack upon one another in a highly ordered manner—thus extending into 
the long axis of the fibril (see Figure 2). The result is stabilization not only between 
β-sheet domains but also between stacked subunits. Fibrils often show a twist along 
their long axis.
Once the requisite region for forming β-sheets becomes available, fibril forma-
tion begins as a nucleation event. Usually small numbers of monomers interact, but 
once the primordial oligomeric fibrillary unit is assembled, further extension can 
occur by aligning new monomers with the growing fibril surface. The kinetics of 
this process are consistent with this scheme, there generally being a lag in assem-
bling the oligomer followed by more rapid extension as subunits are added.
Most amyloid fibrils share relatively common dimensions although their lengths 
often vary. Because the fibrils are so tightly associated within their common nuclei 
of β-sheet domains, they are themselves rather resistant to dissociation (substantial 
free energy of formation) as well as to attack by proteases (regions susceptible to 
Designation Precursor protein Clinical example(s)
AL κ, λ Light chains Myeloma, MGUS
AA Serum amyloid A Secondary
ATTR Transthyretin Nerve/heart
Aβ β-Protein precursor Alzheimer
APrP Prion protein Encephalopathy
Aβ2M β2-Microglobulin Dialysis related
AIAPP Amylin Type II diabetes
ACal (Pro)calcitonin Medullary thyroid carcinoma
AANF Atrial natriuretic factor Atrial amyloid
AαSyn α-Synuclein Parkinson disease
Table 1. 
Examples of pathologic human amyloid fibril proteins [4, 5].
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proteolysis may not be accessible). These molecular features help explain both the 
chronicity and the progressive nature of amyloid disorders.
Amyloid fibrils characteristically bind planar dye molecules. Upon binding 
to fibrils, these dyes can show birefringence when viewed using polarized light 
microscopy, providing a widely used method for identifying amyloid deposits in 
biologic tissues. The dyes Congo Red and Thioflavin T are used most frequently.
Another feature of amyloid fibrils is that they are usually found associated with 
other molecules. These include glycosaminoglycans (which may be responsible for 
calcium binding) as well as the pentraxin protein—“serum amyloid P” (SAP) [13]. 
These common features permit some imaging techniques to identify amyloid fibrils 
radiographically. For example, it is often possible to scan for SAP in order to localize 
amyloid deposits of various types [14].
Reference to Table 1 emphasizes the variety of proteins that can form the 
β-pleated sheet structural units of amyloid fibrils. The proteins generally do not 
share common sequences or large-scale features because the region(s) essential 
for nucleating fibrils is(are) small (recall Figure 2). The protein constituent(s) 
of fibrils can frequently be determined using specific antibodies. The choice of 
antibodies to use is generally aided by the location of the deposit(s) and the clinical 
and/or pathologic context.
4. Fibril formation
As noted above, the fundamental event in amyloid formation is highly specific 
interaction between adjacent (usually) small protein units to form antiparallel (and, 
in some cases, parallel) β-sheets. The native state of the parent protein is generally 
thermodynamically more stable than the amyloid state. However, it is important 
to note that the stability of the amyloid state depends on protein concentration 
while that of the native precursor is largely independent of protein concentration. 
There thus arises a concentration above which the stability of the amyloid state can 
Figure 2. 
Details of Alzheimer Aβ(1-42) fibril emphasizing amino acids 17-42. (A) Ribbon diagram of the core. 
(B) Salt bridges are indicated by the rectangles. (C) View of the “odd” end of the growing fibril showing 
the van der Waals surface as well as the amino acid side chains. The fibril axis is shown, corresponding to 
that in A and B. (D) Simulation of a fibril with four filaments (the adjacent figure shows the filament 
ends and the dimensions). (E) Cryoelectron micrographs of single fibrils [3]. Copyright 2005, National 
Academy of science, used by permission.
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become the same as or even transiently greater than that of the native state. Not 
surprisingly, the complex topology of long proteins makes them unlikely to nucleate 
and extend into stable fibrils. This generally limits formation of amyloid fibrils to 
proteins <150 aa [5].
Once the requisite region for forming the β-sheet becomes accessible, fibril for-
mation begins as a stochastic nucleation event. Usually small numbers of monomers 
interact, but once the primordial oligomeric fibrillary unit is assembled, further 
extension can occur by aligning new monomers with the growing fibril surface. The 
kinetics of this process are consistent with this scheme, there generally being a lag 
in assembling the oligomer followed by more rapid extension as subunits are added.
Because different types of amyloid fibrils have different protein constituents and 
may be found in different locations, it is not always possible to identify common 
features. An important distinction is between fibrils that have soluble, generally blood-
based, precursors and those derived from specific intracellular or organ-limited pro-
teins. Among the former are immunoglobulins (usually κ or λ light chains) and serum 
amyloid A. The latter include hormone precursors such as procalcitonin, prolactin, as 
well as amylin and the β-protein precursor. Prions generally begin intracellularly.
As noted earlier, the protein precursors of amyloid fibrils are usually complex 
with multiple domains, and the critical, nucleating region is often small. Thus, 
many must undergo proteolysis in order to eliminate domains that are topologically 
incompatible with fibril dimensions and structure. In the best-studied examples, 
proteolysis occurs within lysosomes or related organelles although not all sites (or 
responsible proteases) have been determined.
Figure 3 presents a scheme for AA fibril formation from circulating SAA. SAA is 
usually found in association with high-density lipoprotein in the blood, and it must 
dissociate and enter the cell, often using clathrin-mediated endocytosis. Within 
the cell (in lysosomes or related structures), the acidic pH leads to unfolding of the 
precursor as reactive groups are titrated (steps A–C). This likely exposes region(s) 
with increased susceptibility to proteolysis. The considerable free energy of anti-
parallel (or, for some other fibril precursors, parallel) β-pleated sheet formation and 
the relatively high local concentrations of appropriate domains leads to nucleation 
and at least some oligomer formation (steps C, D).
Intracellular oligomeric fibril nucleation ultimately causes organelle disruption 
followed by loss of cellular integrity (step E). The possibility of exosome participa-
tion at this stage has not been excluded. The result is a local mixture of nascent and 
growing amyloid fibrils and cell debris. Having oligomeric “seeds” already formed 
intracellularly, fibril elongation can then be extended. The result becomes a mixed, 
Figure 3. 
Scheme for multiple steps in AA fibril formation from circulating SAA (from [16] see text for details).
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largely acellular, region where amyloid fibrils become the predominant structured 
species (step F) [15, 16].
A contrasting situation can occur in situations where the fibril precursor is not 
only soluble but also intrinsically capable of β structure formation without cleavage. 
Figure 4 shows events for transthyretin (TTR). TTR is a 127 amino acid protein 
circulating in the blood as a stable tetramer that binds thyroid hormone and retin A 
(hence, its name). The TTR monomer itself contains prominent β-sheet domains. If 
the tetramer dissociates, the free monomers can misfold into various forms. Among 
these, some can associate as oligomers which then can be extended into fibrils. TTR 
amyloid fibrils are particularly prone to cause dysfunction in nerves and the heart. 
Interestingly, over 100 amino acid substitutions (i.e., mutations) have been identi-
fied in TTR [17]. Mutations differentially affect tetramer stability—some increase 
it, while others reduce it. Among the latter are several that are associated with 
inherited amyloid diseases, and the Val30Met and Val122Ile mutations have been 
particularly well-studied (affecting nerves and/or the heart). Kinetic and other 
evidence implicates the oligomer form(s) as directly involved in organ dysfunction. 
Amyloid fibrils become detectable by microscopy as the disease progresses. One 
proposed therapeutic strategy involves developing small molecules that stabilize the 
circulating tetramer, hence reducing (or eliminating) dissociation, oligomer forma-
tion, and tissue toxicity [18].
5. Pathologic consequences of amyloid formation
As indicated by Table 1, many disorders can be associated with amyloid deposi-
tion. In many cases, the precise mechanism of pathologic dysfunction is unknown. 
Nevertheless, several notions are important.
First, as noted, some polypeptide hormones are apparently stored in amyloid-
like conformations. These differ from most of the other types in being reversible 
upon hormone release. Only in rare situations do these protein accumulations 
persist as amyloid deposits and become associated with disease.
Second, evolution has often minimized protein sequences that are particularly 
prone to nucleate amyloid fibrils [19]. Many proteins are located in intracellular 
regions or are associated with chaperones that reduce their likelihood of assuming 
alternative conformations. Degradation mechanisms including proteasomes can 
minimize intracellular aggregation.
In so-called “secondary” amyloid disease, the bulk of accumulated fibrils 
likely interferes with cellular and organ function. For example, remarkably large 
Figure 4. 
Scheme for nucleation of TTR amyloid oligomers.
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quantities of AA protein were isolated from the kidneys, liver, and spleen in earlier 
studies [20, 21]. Examining affected tissues by light microscopy clearly shows large 
interruptions in organ structural integrity due to massive amyloid deposits. Similar 
accumulations often accompany “primary” (i.e., immunoglobulin-derived) amy-
loid disease where fragments of immunoglobulin light chains may be found in large 
deposits.
Evidence from other types of amyloid disease indicates that large, microscopi-
cally visible deposits of amyloid fibrils may not always be the initial cause of cell/
organ dysfunction. While fibrils are often seen later in study of affected tissues 
(and, hence, appear as classic “amyloid” by staining), they may be late conse-
quences. Earlier, oligomeric forms may be more disruptive and lead to organ 
dysfunction well before large deposits are detectable by microscopy.
Figure 4 (above) presents a simple scheme for oligomer formation. This is 
likely to occur as a basic pathway in various types of amyloid-related diseases. 
As described above, destabilization of the TTR tetramer occurs extracellularly 
and can lead to oligomers that are relatively small. Various TTR mutations can 
destabilize the tetramer and accelerate this process although even the normal 
protein also appears susceptible in some situations. This likely is a problem for 
various intracellular neurotoxic fibrils and their predecessors (e.g., β-protein 
and α-synuclein) as well [22]. Thus, finding substantial amounts of extracellular 
Congo Red staining deposits may be a late feature of the basic disorder rather than 
the primary cause of dysfunction. As noted above, such material is generally quite 
stable and often resistant to dissociation. Hence, extracellular deposits (or even 
substantial accumulations within organelles) may be the end point of the toxic 
oligomer pathway.
6. Therapeutic approaches to amyloid pathophysiology
As described above, once formed, amyloid fibrils are intrinsically quite stable 
due to intra- and intermolecular bonds and relative inaccessibility to proteases. 
Ideally, disrupting the fibrils themselves would be an appropriate approach to treat-
ing at least some amyloid disorders. In this regard, chaotropic molecules (e.g., urea, 
guanidinium, etc.), often used in the laboratory, are not options for treatment due 
to their toxicity. Alternative agents, compatible with in vivo use have not yet been 
identified. Thus, successful intervention(s) for amyloid disorders must either pre-
vent formation of the precursor(s) or stabilize the protein predecessors of oligomers 
(or their proteolytic cleavage). Several approaches have been introduced, and these 
depend upon the specific type of amyloidosis (recall Table 1).
Immunoglobulin light chain overproduction (“primary” amyloidosis) is basi-
cally a clonal disorder of plasma cell proliferation/overexpression. Here, treatment 
generally depends on suppression or elimination of the responsible cell population. 
This falls into the spectrum of treatment of myeloma and related disorders and 
depends on oncologic approaches.
Amyloid A (SAA) disorders (“secondary” amyloidosis) generally reflect over-
production of the SAA precursor. These usually are related to chronic or periodic 
and recurrent infection/inflammation. The incidence of these has been reduced by 
successful treatment of conditions such as tuberculosis and osteomyelitis. However, 
these and other types of infections and inflammation remain prominent in certain 
parts of the world and can be accompanied by amyloidosis. Genetic disorders such 
as familial Mediterranean fever with recurrent, self-limited inflammatory episodes 
can usually be controlled with agents such as colchicine [23], minimizing SAA 
synthesis and AA amyloid accumulation.
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For TTR-related disorders several approaches are recognized. First, because the 
liver is the main site for the synthesis of TTR, liver transplantation can eliminate 
production of the mutant TTR protein. Although this has been used successfully, 
it is a complex process with its own intrinsic short- and long-term complications 
[24]. Second, synthesis of the responsible mutant protein can be suppressed. 
Several approaches based on specifically interrupting stability of TTR messenger 
RNA through RNAi have been developed. (Carriers of TTR mutations are usually 
heterozygotes, so these approaches generally reduce levels of both mutant and 
normal TTR—apparently, a reduced concentration of TTR is well-tolerated.) Third, 
the circulating tetramer can be stabilized by exogenous agents (e.g., Tafamidis™) 
to shift the equilibrium away from dissociation (and, hence, minimize oligomer 
formation). These approaches show promise [25, 26].
For neurologic disorders where the underlying problem is likely intracellular 
(e.g., α-synuclein and β-protein), the above approaches have not been feasible. It is 
more likely that clarification of complex intracellular pathways will be required in 
order to develop approaches to prevent and/or interrupt fibril accumulation in these 
and related conditions.
7. Conclusions
Amyloid formation and related disorders present examples of situations where 
there is fundamental dependence on protein structure, its variation(s), abundance, 
and the consequences of alternative conformation(s). Because the molecules 
involved are quite different for each type of amyloid disease, different organs may 
be involved, and stabilizing or eliminating the precursors likely will vary. Successful 
therapeutic intervention will likely be unique to each type of amyloidosis. The basic 
concerns are similar, however, and considerable progress has already clarified both 
the problem(s) and the options.
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